Zafgen prices upsized IPO at $16, the high end of the range

Comment

Shutterstock photo

Zafgen, a biotech developing a treatment for severe obesity and hunger-related disorders, raised $96 million by offering 6 million shares (upsized from 5 million) at $16, the high end of the range of $14 to $16. Zafgen plans to list on the NASDAQ under the symbol ZFGN. Zafgen initially filed confidentially on 1/31/2014. Leerink Partners and Cowen & Company acted as lead managers on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.



This article appears in: News Headlines , IPOs


More from Renaissance Capital

Subscribe






Renaissance Capital
Contributor:

Renaissance Capital

IPOs
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com